• Home
• Responsibility
• CR Report 2005
• Managing CR
• Stakeholder engagement

Stakeholder engagement

Engaging with the different groups that have an interest in the way we operate is an important part of responsible business practice. Our stakeholders include employees, investors, patients, doctors, governments, NGOs, multilateral organisations, local communities, suppliers and the scientific community. By listening to them and being open about our views and actions we can build trust and address their concerns.

Most of this discussion takes place in the normal course of business. For example our scientists meet regularly with academics, researchers and other pharmaceutical companies. Through our access to medicine and community investment programmes we collaborate with NGOs, multilateral agencies, governments and community groups. More information is available on stakeholder interaction in the following sections: Access to medicines, Animal research, Employees, Suppliers, and Government and external affairs.

In 2005 we established a panel of external stakeholders to provide ongoing advice and comment on our EHS performance. The panel is facilitated by The Environment Council, an independent NGO. See EHS management.

We also seek stakeholder feedback to inform our approach to managing and reporting on CR issues. In 2005 this included:

• Engagement with socially responsible investors (SRI). During 2005 we had more than 30 meetings with SRI analysts and discussed issues including access to medicines, animal rights, supply chain, sales and marketing ethics and clinical trials. Fifteen SRI analysts attended our annual corporate responsibility (CR) briefing and met with 12 senior GSK managers.
• A survey of 51 Corporate Responsibility opinion leaders in Europe, the UK and the US. Participants included academics, CR organisations, customers, government agencies, investors, the media, multilateral agencies and NGOs.
• A survey of GSK employees. This assessed employee awareness of CR issues and sought their views on the key CR issues for GSK.

This section contains a summary of the feedback we received through these channels and details of how we are responding.

Back to top